All In Biotech

Drug Trial Radar · NCT01027429

Simplified Antibiotic Therapy for Sepsis in Young Infants

Simplified Antibiotic Regimens for the Management of Sepsis in Young Infants in First-level Facilities: Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,543 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,543

Actual

Start

Dec 2009

Primary completion

Dec 2013

Study completion Dec 2013

Sponsor

Lead sponsor
Aga Khan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Save the Children; World Health Organization; London School of Hygiene and Tropical Medicine; Emory University
First posted
Dec 8, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 59 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial evaluates primary care clinic-based simplified antibiotic therapy options for young infants, 0-59 days old in high neonatal mortality settings in peri-urban Karachi where hospital referral is frequently refused by families.

Conditions

  • Neonatal Sepsis
  • Sepsis
  • Infection

Interventions

  • procaine penicillin and gentamicinDrug

    procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days

  • amoxicillin and gentamicinDrug

    oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days

  • procaine penicillin, gentamicin, amoxicillinDrug

    procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment failureTime frame: within 7 days of enrolment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ali Akber Shah Goth

    Karachi, Sindh, Pakistan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.